Survival analysis of transplant-eligible newly-diagnosed multiple myeloma patients harboring t(4;14), t(14;16), and/or del(17p) in the real-world setting

Año de publicación:

2023

PI:

David Garrido

Revista / Publicación

Curr Probl Cancer

Cita:

Curr Probl Cancer. 2023 Feb;47(1):100916.

DOI:

10.1016/j.currproblcancer.2022.100916.
Descargar
Ver publicación

Otras publicaciones

  • 2024

The Latin American experience in POEMS syndrome

Descargar
Leer más
  • 2023

Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America

Descargar
Leer más
  • 2023

Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group

Descargar
Leer más
  • 2022

Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America

Descargar
Leer más
  • 2022

Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study

Descargar
Leer más
  • 2020

Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study

Descargar
Leer más